Loading...
NOVO B logo

Novo Nordisk A/SCPSE:NOVO B Stock Report

Market Cap DKK 1.5t
Share Price
DKK 338.70
My Fair Value
DKK 465
27.2% undervalued intrinsic discount
1Y-61.3%
7D-5.5%
Portfolio Value
​
View

Novo Nordisk A/S

CPSE:NOVO B Stock Report

Market Cap: DKK 1.5t

Novo Nordisk (NOVO B) Stock Overview

Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details

NOVO B fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance5/6
Financial Health3/6
Dividends4/6

Rewards

Trading at 73.3% below our estimate of its fair value

Earnings are forecast to grow 9.05% per year

Earnings grew by 23.5% over the past year

Trading at good value compared to peers and industry

Risk Analysis

High level of non-cash earnings

Highly volatile share price over the past 3 months compared to the Danish market

Unstable dividend track record

Has a high level of debt


NOVO B Community Fair Values

Create Narrative

See what 977 others think this stock is worth. Follow their fair value or set your own to get alerts.

NOVO B logo
Novo Nordisk

GLP-1 Therapy Penetration And Global Launches Will Unlock Market Potential

Key Takeaways Vast global demand for GLP-1 therapies and metabolic disease treatments offers long-term revenue growth, as adoption and access increase amid rising obesity and aging trends. Expanded product launches, manufacturing investments, and innovation in new disease areas are set to boost market reach, support resilient earnings, and reduce supply constraints.
View narrative
DKK 465.30
FV
27.2% undervalued intrinsic discount
8.34%
Revenue growth p.a.
10users have liked this narrative
3users have commented on this narrative
439users have followed this narrative
6 days ago author updated this narrative
NOVO B logo
Novo Nordisk

Urbanization And Aging Trends Will Amplify GLP-1 Adoption

Key Takeaways International expansion and supply ramp-up position the company for robust, sustained growth by unlocking untapped patient pools and converting demand into profit. Innovation in pipeline, digital health leadership, and streamlined operations broaden revenue streams and boost efficiency, strengthening dominance in chronic disease management.
View narrative
DKK 620.00
FV
45.4% undervalued intrinsic discount
13.48%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
5 days ago author updated this narrative
NOVO B logo
Novo Nordisk

Regulatory And Generic Challenges Will Compress Margins But Uplift Pipeline

Key Takeaways Heavy reliance on blockbuster therapies and looming patent expirations expose Novo Nordisk to revenue pressure from biosimilar competition and pricing headwinds. Expanding international demand is offset by rising economic inequality, regulatory risks, and escalating operating costs, threatening long-term growth and margins.
View narrative
DKK 340.00
FV
0.4% undervalued intrinsic discount
4.51%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
6 days ago author updated this narrative
NOVO B logo
Novo Nordisk

EU#2 - From Humble Beginnings to Global Powerhouse

Novo Nordisk, one of the world’s leading pharmaceutical companies, has a unique and inspiring origin story rooted in personal tragedy and scientific curiosity. The company’s roots date back to the 1920s, when Danish Nobel laureate August Krogh, a renowned physiologist, and his wife Marie, who suffered from type 2 diabetes, traveled to Canada.
View narrative
DKK 851.04
FV
60.2% undervalued intrinsic discount
22.49%
Revenue growth p.a.
19users have liked this narrative
11users have commented on this narrative
61users have followed this narrative
4 months ago author updated this narrative
View Stock Community

Novo Nordisk A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novo Nordisk
Historical stock prices
Current Share PriceDKK 338.70
52 Week HighDKK 934.20
52 Week LowDKK 287.60
Beta0.32
1 Month Change4.84%
3 Month Change-34.45%
1 Year Change-61.30%
3 Year Change-14.61%
5 Year Change58.31%
Change since IPO12,467.72%

Recent News & Updates

Recent updates

Novo Nordisk's (CPH:NOVO B) Profits May Not Reveal Underlying Issues

Aug 13
Novo Nordisk's (CPH:NOVO B) Profits May Not Reveal Underlying Issues

Analysts Have Been Trimming Their Novo Nordisk A/S (CPH:NOVO B) Price Target After Its Latest Report

Aug 08
Analysts Have Been Trimming Their Novo Nordisk A/S (CPH:NOVO B) Price Target After Its Latest Report

Novo Nordisk A/S' (CPH:NOVO B) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Jul 31
Novo Nordisk A/S' (CPH:NOVO B) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Jul 24
Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novo Nordisk (CPH:NOVO B) On Your Watchlist?

Jun 23
Is Now The Time To Put Novo Nordisk (CPH:NOVO B) On Your Watchlist?

Novo Nordisk A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 09
Novo Nordisk A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Why We're Not Concerned About Novo Nordisk A/S' (CPH:NOVO B) Share Price

Apr 24
Why We're Not Concerned About Novo Nordisk A/S' (CPH:NOVO B) Share Price
User avatar

EU#2 - From Humble Beginnings to Global Powerhouse

CagriSema – a combination therapy for obesity and diabetes that may be even more effective than Wegovy.

We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Apr 07
We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Mar 14
Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Feb 28
Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Novo Nordisk will dominate with GLP-1 products boosting an 8% revenue spike

Are there any products or services that could move sales or earnings meaningfully?Most Immediate Catalyst (1–2 Years):Established GLP-1 Products:Ozempic & Rybelsus: driving robust sales and market pe

Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

Feb 10
Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Feb 07
The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Jan 09
Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Dec 23
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Nov 13
Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09
Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
User avatar

Expanding Horizons And Innovation Drive Bold Growth In Pharma's Global Landscape

Strategic market expansion and supply chain investments are set to boost Novo Nordisk's revenue growth through increased production and broader geographical reach.

Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Nov 01
Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Oct 09
Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Shareholder Returns

NOVO BDK PharmaceuticalsDK Market
7D-5.5%-4.7%-2.4%
1Y-61.3%-59.6%-38.6%

Return vs Industry: NOVO B underperformed the Danish Pharmaceuticals industry which returned -59.6% over the past year.

Return vs Market: NOVO B underperformed the Danish Market which returned -38.6% over the past year.

Price Volatility

Is NOVO B's price volatile compared to industry and market?
NOVO B volatility
NOVO B Average Weekly Movement8.8%
Pharmaceuticals Industry Average Movement4.5%
Market Average Movement4.4%
10% most volatile stocks in DK Market8.7%
10% least volatile stocks in DK Market2.5%

Stable Share Price: NOVO B's share price has been volatile over the past 3 months compared to the Danish market.

Volatility Over Time: NOVO B's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Danish stocks.

About the Company

FoundedEmployeesCEOWebsite
192378,387Maziar Doustdarwww.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVO B fundamental statistics
Market capDKK 1.54t
Earnings (TTM)DKK 111.07b
Revenue (TTM)DKK 311.94b
13.6x
P/E Ratio
4.8x
P/S Ratio

Is NOVO B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVO B income statement (TTM)
RevenueDKK 311.94b
Cost of RevenueDKK 49.11b
Gross ProfitDKK 262.83b
Other ExpensesDKK 151.76b
EarningsDKK 111.07b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Nov 05, 2025

Earnings per share (EPS)25.00
Gross Margin84.26%
Net Profit Margin35.61%
Debt/Equity Ratio59.1%

How did NOVO B perform over the long term?

See historical performance and comparison

Dividends

3.4%
Current Dividend Yield
47%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/09 23:32
End of Day Share Price 2025/09/09 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 73 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research